TrialCancer biology & therapy2016

Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.

Jessica D Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.